69 results about "Cellular Assay" patented technology

We describe herein a cell-based multiplexing technique called detectable cell barcoding (DCB). In DCB, each individual sample is labeled with a different DCB signature that distinguishes each sample by one or both of detected intensity or type of detection characteristic. The samples are then combined and analyzed for a detectable characteristic of interest (e.g., presence of an analyte). By employing multiple distinct DCB labels at varying concentrations, one can perform multiplex analyses on up to hundreds or thousands (or more) of cell samples in a single reaction tube. DCB reduces reagent consumption by factors of 100-fold or more, significantly reduces data acquisition times and allows for stringent control sample analysis.

The present invention includes devices, systems, and methods for assaying cells using cell-substrate impedance monitoring. In one aspect, the invention provides cell-substrate impedance monitoring devices that comprise electrode arrays on a nonconducting substrate, in which each of the arrays has an approximately uniform electrode resistance across the entire array. In another aspect, the invention provides cell-substrate monitoring systems comprising one or more cell-substrate monitoring devices comprising multiple wells each having an electrode array, an impedance analyzer, a device station that connects arrays of individual wells to the impedance analyzer, and software for controlling the device station and impedance analyzer. In another aspect, the invention provides cellular assays that use impedance monitoring to detect changes in cell behavior or state. In some preferred aspects, the assays are designed to investigate the affects of compounds on cells, such as cytotoxicity assays. In other preferred aspects, the assays are designed to investigate the compounds that effect IgE-mediated responses of cells to antigens.

Disclosed herein are methods for single-cell sequencing. In some examples, the methods include enriching a sample comprising a plurality of cells for cells of interest to produce an enriched cell sample; isolating one or more cells of interest in the enriched cell sample; and obtaining sequence information of one or more polynucleotides from each of the one or more isolated cells. Obtaining sequence information may include generating a molecularly indexed polynucleotide library from the one or more isolated cells. Enriching the sample may include focusing cells of interest in the sample using acoustic focusing.

The present invention relates to the field of molecular diagnostics, and in particular to diagnostics based on a liquid crystal assay format. In particular, the present invention provided improved substrates and methods of using liquid crystal assays for quantitating the amount of an analyte in a sample. The present invention also provides materials and methods for detecting non-specific binding of an analyte to a substrate by using a liquid crystal assay format.

The present invention includes devices, systems, and methods for assaying cells using cell-substrate impedance monitoring. In one aspect, the invention provides cell-substrate impedance monitoring devices that comprise electrode arrays on a nonconducting substrate, in which each of the arrays has an approximately uniform electrode resistance across the entire array. In another aspect, the invention provides cell-substrate monitoring systems comprising one or more cell-substrate monitoring devices comprising multiple wells each having an electrode array, an impedance analyzer, a device station that connects arrays of individual wells to the impedance analyzer, and software for controlling the device station and impedance analyzer. In another aspect, the invention provides cellular assays that use impedance monitoring to detect changes in cell behavior or state. In some preferred aspects, the assays are designed to investigate the affects of compounds on cells, such as cytotoxicity assays. In other preferred aspects, the assays are designed to investigate the compounds that effect IgE-mediated responses of cells to antigens.

Devices and methods for implementing cell-based assays and long-term cell culture. The device and method are based on digital microfluidics (DMF) which is used to actuate nanoliter droplets of reagents and cells on a planar array of electrodes. DMF method is suitable for assaying and culturing both cells in suspension and cells grown on surface (adherent cells). This method is advantageous for cell culture and assays due to the automated manipulation of multiple reagents in addition to reduced reagent use and analysis time. No adverse effects of actuation by DMF were observed in assays for cell viability, proliferation, and biochemistry. These results suggest that DMF has great potential as a simple yet versatile analytical tool for implementing cell-based assays and cell culture on the microscale.

The present invention relates to the field of molecular diagnostics. In particular, the present invention provided improved substrates and methods of using liquid crystals and other biophotonically based assays for quantitating the amount of an analyte in a sample. The present invention also provides materials and methods for detecting non-specific binding of an analyte to a substrate by using a liquid crystal or other biophotonically based assay formats.

High throughput and automated cellular disruption systems that substantially uniformly disrupt cells as part of cellular motility assays as wells as other assay types are provided. In addition, various system components, including holding blocks, holding block loading devices, and system software, are also provided. Moreover, related methods that utilize these systems and system components are additionally provided.

The present invention relates to the field of molecular diagnostics, and in particular to diagnostics based on a liquid crystal assay format. In particular, the present invention provided improved substrates and methods of using liquid crystal assays for quantitating the amount of an analyte in a sample. The present invention also provides materials and methods for detecting non-specific binding of an analyte to a substrate by using a liquid crystal assay format.

The invention discloses a series drugs for resisting novel coronavirus SARS-CoV-2 and application thereof. In-vitro cell test results show that compounds disclosed in the invention can significantly inhibit infection of SARS-CoV-2 on normal cells, have an inhibition effect on novel coronavirus SARS-CoV-2 at a cellular level, can significantly reduce the virus titer of novel coronavirus in cells and inhibit proliferation of the novel coronavirus in cells, and has dose dependence. Therefore, the compounds can be used as inhibitors for novel coronavirus SARS-CoV-2, and has the potential of treating COVID-19 pneumonia caused by infection of a human body with the coronavirus SARS-CoV-2 or other diseases caused by infection of animals with the coronavirus SARS-CoV-2.

This invention provides compositions and methods useful for the processing of a tissue sample and the preparation of cells, cell aggregates and / or tissue fragments. The invention provides two-stage filer devices and two-membrane devices. Cell aggregates and / or tissue fragments prepared using such devices and according to methods of the present invention can be used in a variety of assay systems, including, but not limited to, drug validation assays, drug screening assays, proliferation assays, metabolic assays, metastasis assays, angiogenesis assays, binding assays, biochemical assays, cellular assays, genetic assays, and the like.

Disclosed are nitro-substituted squaraine reporter dyes and methods using such dyes for detecting nitroreductase enzyme activity and nitroreductase gene expression in cellular assays. The dyes are of the structure:in which Z1 and Z2 independently represent a phenyl or a naphthyl ring system; X and Y are selected from oxygen, sulphur, —CH═CH— and the group:R1 and R2 are selected from C1-C4 alkyl, —(CH2)n—P, —{(CH2)2—O}p—R6 and group W; where P is selected from COOR7, SO3− and OH, W is mono- or di-substituted nitrobenzyl, R6 is methyl or ethyl, R7 is selected from H, C1-C4 alkyl and CH2OC(O)R8, where R8 is methyl, or t-butyl, n is an integer from 1 to 10, and p is an integer from 1 to 3; R3 and R4 are selected from hydrogen, NO2, halogen, SO3−, C1-C4 alkoxy and —(CH2)m—COOR7; where R7 is hereinbefore defined and m is 0 or an integer from 1 to 5; R5 is C1-C6 alkyl optionally substituted with COOR7, SO3−, or OH; where R7 is hereinbefore defined; and at least one of groups R1, R2, R3 and R4 comprises at least one NO2 group. Also provided are methods for screening for a test agent whose effect upon nitroreductase enzyme activity and nitroreductase gene expression is to be determined.

The invention discloses a cartilage tissue engineering fiber scaffold material and a preparation method thereof. The method comprises the following steps: preparing mixed sol by mixing high-biocompatibility degradable biological materials such as konjac glucomannan, sodium hyaluronate and nano-hydroxyapatite which serve as basic materials; preparing modified sol by a lactic acid solution modifying and microwave process; performing wet spinning; and preparing a degradable fiber scaffold for regeneration and repair of a konjac glucomannan / sodium hyaluronate / nano-hydroxyapatite composite cartilage tissue by a programmable two-dimensional mobile platform. The scaffold has the advantages of simple preparation process, adjustable degradation rate, low cost, excellent tissue compatibility and the like. A preliminary cell test and an animal test indicate that the scaffold can be commonly used in vivo (such as cartilage defect lesion parts), and is a multifunctional composite material which can promote repair of cartilage defect, is antibacterial and can adjust the in-vivo degradation rate.

Data processing system for generating representations and analyses of cytometric information for:—loading one set of data including:—one image of two wells on a plate each having one cell in a predetermined biological condition, each image being acquired with a microscope;—features of each cell from each image;—processing loaded data for obtaining representations and analyses of the data, from:—Histogram in one dimension;—Scattergram in two-dimensions;—Density in two-dimensions;—Plate layout management;—Cell montage;—Field;—Plate heatmap;—Dose response with regrouping of replicates;—Statistics information percentage of cell in different gates;—zFactor calculation with regrouping of replicates;—List of well for selection and list of biological condition for selection;—Statistics export capability;—Ready to print layout capability on the selected well or biological condition or all wells and biological conditions.

Disclosed are methods related to label-free biosensor cellular assays to classify multienzyme complex modulators in live cells. Disclosed are also methods related to the identification of purinosome disrupting Casein Kinase II (CK2) inhibitors, and methods related to the use of purinosome disrupting CK2 inhibitors as therapeutic agents for modulating CK2 activity and purine synthesis pathway, and for improving prevention and treatment of CK2 associated cancers, viral infection and inflammation conditions.

The invention discloses an application of GC376 in preparation of a novel coronavirus SARS-CoV-2 inhibitor. In-vitro cell test results prove that GC376 can notably inhibit infection of SARS-CoV-2 on normal cells, has an inhibition function on SARS-CoV-2 in terms of cell level, can notably reduce toxicity of the virus in cells and inhibit proliferation of the virus in the cells and is dose-dependent. Therefore, GC376 can serve as the novel coronavirus SARS-CoV-2 inhibitor and has the potential of treating COVID-19 caused by the virus or other diseases caused after animals are infected.

In one aspect, the present invention relates to a system 100 for automated cellular assay data analysis. The system 100 comprises a virtual assay module (VAM) 115 operable to generate simulated images of cell responses to one or more stimuli. The system 100 also comprises a comparator module 116 operable to compare the actual and simulated images, and an analysis module 117 operable to quantify the differences between phenotypes represented by the actual and simulated images. Various aspects and embodiments of present invention may account for stochastic variations in the response of single cells, to provide additional useful information relating to, for example, toxological effects and / or for use as part of a feedback mechanism to refine dynamically a virtual assay model such that it is not limited by way of there being only inadequate static fitting expressions available.

The present invention relates to cryopreserved cell cultures, methods for cryopreserving cells and methods for conducting cellular assays on such cells. A cryopreserved cell culture of the invention comprises a container having at least a surface which is coated with poly-lysine and frozen cells supported on the surface.

The present invention concerns a tester protein for identifying and / or monitoring protease activity in a cellular assay suitable for high throughput screenings by growth selection, wherein the tester polypeptide is a non-regulatory protein carrying a protease cleavage sequence. Upon co-expression of the protease recognizing said cleavage sequence the tester protein is inactivated, which influences the growth and / or survival of the host cells under the chosen conditions. However, in the presence of protease inhibitor the growth phenotype is reversed. The system can be used to identify proteases, protease inhibitors, and protease cleavage sites.

This invention relates to the field of biological assays where cells can be classified and enumerated using flow cytometry optical instrumentation. The invention combines information from multi-angle, light scatter from the cell itself and multi-angle light scatter from small, optically resonant particles that are selectively bound to surface molecules on the cell to carry out classification and enumeration. This light scatter method enables an instrumentation system that is simple to use, inexpensive to build, and mechanically robust; making it suitable for use in remote clinical environments.

The present invention relates generally to the fields of molecular biology and cancer. More specifically, the invention concerns methods and compositions useful for diagnosing and assessing a subject's response to therapy.

The invention discloses a pharmaceutical composition. The pharmaceutical composition is composed of GC376 and GS-441524. In-vitro cell test results show that the composition can inhibit proliferationof novel coronavirus SARS-CoV-2 in cells, has a better drug effect than a single drug, has a significant synergistic effect, can be used as a novel coronavirus SARS-CoV-2 inhibitor, is used for treating COVID-19 pneumonia, and has the advantages of good curative effect, high safety, no toxic or side effects, capability of reducing drug resistance of viruses and toxic and side effects of drugs, etc.

The invention relates to an injector which is installed on an automatic cell sedimentation tablet compressing machine and conducts rapid abstraction and push on the liquid sample of cast-off cells that contain rather much mucilage. The injector is characterized in that a plug is inserted into the needle tube of the injector and provided with at least two groove channels which are internally communicated with the tube of the injector. The injector can abstract and push sample more rapidly, the sample does not spill over and the channel is not blocked completely, thus being conducive to realizing automation. A mould used for manufacturing the utility model is simple and the assembly of semi-manufactured goods is convenient; therefore, the injector which has low cost and is disposable to prevent crossing contamination can be manufactured on a large scale.

The invention discloses a detection method for a slow virus infected cell. The method comprises the steps of: synthesizing a single stranded random oligonucleotide library, and infecting an HEK293 cell with MOI (multiplicity of infection)=5; incubating the random oligonucleotide library with a target molecule together for 1h at a temperature of 4DEG C, then washing the monolayer of the cell with PBS (phosphate buffer solution); conducting enzymatic hydrolysis to gain a cell which is resuspended in 0.5ml of H2O at a temperature for 5min so as to release a combined oligonucleotide ligand candidate molecule, generating a new subordinated library through PCR (polymerase chain reaction) or RT-PCR (reverse transcription-polymerase chain reaction), then carrying out combination with the target molecule for a second round screening, repeating the circulation for several times so as to screen out a nucleic acid ligand able to be specifically bound with the target molecule, marking the nucleic acid ligand with Cy5, and incubating the nucleic acid ligand with the slow virus infected HEK293 cell together, performing flow cytometry analysis after washing, cloning the identified nucleic acid ligand to a vector for sequence analysis. The method of the invention can detect a slow virus infected human tissue cell rapidly, simply and effectively, and also can be used for detection of other virus infection or the generation processes of other diseases.

The invention discloses kumquat essential oil and a preparation method and application thereof. The kumquat essential oil is a pure natural substance extracted from kumquat fruits. The kumquat essential oil is obtained through dry steaming extraction, main active ingredients and content in the kumquat essential oil are measured by utilizing GC-MS, and then a hypertension animal model test is established, so that the kumquat essential oil and the active ingredients thereof are proved to be capable of obviously reducing vasoconstriction pressure and regulating vasodilatation factors such as angiotensin II and the like and also capable of relieving target organ damage caused by hypertension; and a cell test proves that the kumquat essential oil is capable of regulating the angiotensin II to induce HUVEC cell viability. Therefore, the kumquat essential oil has good prevention and treatment effects on renal hypertension.